Figure 3
Angiotensin II infusion promotes cognitive impairment and blood-brain barrier breakdown which is prevented by co-treatment with hydralazine. A: The effect of hydralazine on blood pressure in mice infused with vehicle or angiotensin II (n=7-8). All data are mean ± S.E.M. *P<0.05 vs vehicle. Two-way ANOVA with Tukey’s test.B: Representative heatmap plots showing interaction between familiar and novel objects in mice infused with vehicle, angiotensin II, vehicle + hydralazine and angiotensin II + hydralazine. C:Effect of angiotensin II infusion and co-treatment of hydralazine on recognition memory (n=9-12). All data are mean ± S.E.M. *P<0.05. One-sample t-test vs. 50%. D:Representative images showing IgG deposition (Alexa Flour 555, red) in hippocampus of mice infused with vehicle, angiotensin II, vehicle + hydralazine and angiotensin II + hydralazine. Nuclei are identified by DAPI counter-stain (blue). Scale bar = 200 µm. E: Effect of angiotensin II infusion and co-treatment of hydralazine on IgG deposition in the hippocampus (n=7-8). All data are mean ± S.E.M. *P<0.05. Two-way ANOVA with Sidak’s test. F:Correlation between IgG deposition in hippocampus and systolic blood pressure (R2=0.13, P=0.05). G: Representative images showing IgG deposition (Alexa Flour 555, red) in cortex of mice infused with vehicle, angiotensin II, vehicle + hydralazine and angiotensin II + hydralazine. Nuclei are identified by DAPI counter-stain (blue). Scale bar = 200 µm. H: Effect of angiotensin II infusion and co-treatment of hydralazine on IgG deposition in the cortex (n=7-8). All data are mean ± S.E.M. *P<0.05. Two-way ANOVA with Sidak’s test. I:Correlation between IgG deposition in cortex and systolic blood pressure (R2=0.26, P<0.05).